The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom

Clin Oncol (R Coll Radiol). 1997;9(3):141-3. doi: 10.1016/s0936-6555(97)80067-2.
No abstract available

Publication types

  • Clinical Trial
  • Editorial
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Research Design
  • Tamoxifen / therapeutic use*
  • Time Factors

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen